The Phase 2 trial published in the New England Journal of Medicine in 2023 reported up to 24% average weight loss at 48 weeks at the highest dose the largest number ever recorded for an obesity drug
Continued authorization: Many states require evidence of ongoing weight loss (typically 5% or more body weight loss within 12 to 16 weeks) to continue coverage Tips for Successful Prior Authorization Document BMI, comorbidities, and lifestyle counseling at every patient visit, not just the visit where you submit the PA Include specific, detailed language about failed interventions in your clinical notes Submit the PA with complete documentation on the first attempt to avoid delays from requests for additional information Use peer-reviewed clinical trial data (STEP, SURMOUNT) to support your letter of medical necessity Track PA timelines and follow up proactively rather than waiting for automatic denial at the deadline How to Appeal a Medicaid Denial for Weight Loss Medication When Medicaid does not cover weight loss shots on the first attempt, an appeal is often warranted and frequently successful
It does not mean a peptide is proven for every claim attached to it
Of the 361 overweight or obese patients who were prescribed semaglutide, 20 developed NAION
The absence of this protective layer of glycosaminoglycans in patients with interstitial cystitis increases inflammation, which leads to cyst formation and swelling with subsequent pain and irritation.7 In one study, approximately half of the women diagnosed with interstitial cystitis reported symptoms of dysuria.8 Other causative factors of interstitial cystitis have been suggested, including chronic or subclinical infection, autoimmunity, and genetic susceptibility, any of which could be responsible for initiating the inflammatory response
